Shaashua Lee, Eckerling Anabel, Israeli Boaz, Yanovich Gali, Rosenne Ella, Fichman-Horn Suzana, Ben Zvi Ido, Sorski Liat, Haldar Rita, Satchi-Fainaro Ronit, Geiger Tamar, Sloan Erica K, Ben-Eliyahu Shamgar
Sagol School of Neuroscience and School of Psychological Sciences, Tel Aviv University, 69978, Tel Aviv, Israel.
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
BMC Biol. 2020 Nov 6;18(1):163. doi: 10.1186/s12915-020-00893-2.
Numerous case studies have reported spontaneous regression of recognized metastases following primary tumor excision, but underlying mechanisms are elusive. Here, we present a model of regression and latency of metastases following primary tumor excision and identify potential underlying mechanisms.
Using MDA-MB-231 human breast cancer cells that express highly sensitive luciferase, we monitored early development stages of spontaneous metastases in BALB/c nu/nu mice. Removal of the primary tumor caused marked regression of micro-metastases, but not of larger metastases, and in vivo supplementation of tumor secretome diminished this regression, suggesting that primary tumor-secreted factors promote early metastatic growth. Correspondingly, MDA-MB-231-conditioned medium increased in vitro tumor proliferation and adhesion and reduced apoptosis. To identify specific mediating factors, cytokine array and proteomic analysis of MDA-MB-231 secretome were conducted. The results identified significant enrichment of angiogenesis, growth factor binding and activity, focal adhesion, and metalloprotease and apoptosis regulation processes. Neutralization of MDA-MB-231-secreted key mediators of these processes, IL-8, PDGF-AA, Serpin E1 (PAI-1), and MIF, each antagonized secretome-induced proliferation. Moreover, their in vivo simultaneous blockade in the presence of the primary tumor arrested the development of micro-metastases. Interestingly, in the METABRIC cohort of breast cancer patients, elevated expression of Serpin E1, IL-8, or the four factors combined predicted poor survival.
These results demonstrate regression and latency of micro-metastases following primary tumor excision and a crucial role for primary tumor secretome in promoting early metastatic growth in MDA-MB-231 xenografts. If generalized, such findings can suggest novel approaches to control micro-metastases and minimal residual disease.
众多病例研究报告了原发性肿瘤切除后已确认转移灶的自发消退,但潜在机制尚不清楚。在此,我们提出了一个原发性肿瘤切除后转移灶消退和潜伏期的模型,并确定了潜在的机制。
使用表达高度敏感荧光素酶的MDA-MB-231人乳腺癌细胞,我们监测了BALB/c nu/nu小鼠自发转移的早期发展阶段。切除原发性肿瘤导致微转移灶显著消退,但大转移灶未消退,并且在体内补充肿瘤分泌组可减少这种消退,这表明原发性肿瘤分泌的因子促进早期转移生长。相应地,MDA-MB-231条件培养基增加了体外肿瘤增殖和黏附,并减少了细胞凋亡。为了确定特定的介导因子,对MDA-MB-231分泌组进行了细胞因子阵列和蛋白质组分析。结果确定了血管生成、生长因子结合和活性、黏着斑以及金属蛋白酶和细胞凋亡调节过程的显著富集。中和这些过程中MDA-MB-231分泌的关键介质IL-8、血小板衍生生长因子-AA(PDGF-AA)、丝氨酸蛋白酶抑制剂E1(PAI-1)和巨噬细胞迁移抑制因子(MIF),均可拮抗分泌组诱导的增殖。此外,在原发性肿瘤存在的情况下对它们进行体内同时阻断可阻止微转移灶的发展。有趣的是,在乳腺癌患者的METABRIC队列中,丝氨酸蛋白酶抑制剂E1、IL-8或这四种因子联合表达升高预示着生存率较差。
这些结果证明了原发性肿瘤切除后微转移灶的消退和潜伏期,以及原发性肿瘤分泌组在促进MDA-MB-231异种移植瘤早期转移生长中的关键作用。如果这些发现具有普遍性,那么可能提示控制微转移灶和最小残留疾病的新方法。